Testing when adaptive data acquisition can replace fixed measurement plans
arXiv:2607. 27651v2 Announce Type: replace Abstract: Learned rules select samples for follow-up measurements in high-throughput experiments.
arXiv:2607. 27651v1 Announce Type: new Abstract: Adaptive laboratories choose measurements during experiments, yet most methods begin after adaptation is permitted.
arXiv:2607. 27651v2 Announce Type: replace Abstract: Learned rules select samples for follow-up measurements in high-throughput experiments.
arXiv:2606. 02902v1 Announce Type: cross Abstract: Deep reinforcement learning (DRL) is increasingly applied to de novo molecular design, but choices in data, rewards, and evaluation can yield uneven performance across disease areas and chemotypes.
arXiv:2607. 05462v1 Announce Type: cross Abstract: As AI agents are incorporated into life science workflows, the capabilities that speed discovery might also enable misuse.
arXiv:2608. 05235v1 Announce Type: cross Abstract: Research agents increasingly conduct multi-round machine-learning experiments in industrial recommendation settings and retain the resulting trajectories to guide later decisions.
arXiv:2606. 19245v1 Announce Type: new Abstract: Artificial intelligence (AI) agents promise to accelerate drug discovery by compressing interpretation and decision-making loops, but practical deployment requires trusted evaluation on realistic program decisions.
arXiv:2604. 11305v3 Announce Type: replace Abstract: Conformal selection (CS) uses calibration data to identify test inputs whose unobserved outcomes are likely to satisfy a pre-specified minimal quality requirement, while controlling the false discovery rate (FDR).
arXiv:2606. 04262v1 Announce Type: cross Abstract: Large language models (LLMs) are increasingly used for everyday health questions, including whether a user can safely take another dose of an over-the-counter (OTC) medication.
Frontier large language models (LLMs) are increasingly integrated into scientific workflows, yet their growing biological capabilities may outpace current safeguards. To assess the biological risks of frontier models, we develop Intern-BioBreaker, a specialized bio-red-teaming model, together with an integrated computational-to-physical framework that couples model-level stress testing with wet-lab validation.
arXiv:2608. 10792v1 Announce Type: new Abstract: Autonomous chemistry increasingly depends on environments in which agents can repeatedly act, observe, and adapt.
arXiv:2608. 03606v1 Announce Type: new Abstract: Clinical development is sequential decision-making under uncertainty, where a sponsor must plan a portfolio of experiments from heterogeneous evidence.
arXiv:2606. 00555v1 Announce Type: new Abstract: Structure-based drug design increasingly employs LLM agents to iteratively refine ligands against a target pocket, yet a viable ligand must satisfy two often-conflicting objectives -- binding affinity and druggability -- which single optimization steps rarely improve together.
arXiv:2606. 28939v1 Announce Type: new Abstract: Behavior-cloned diffusion policies are expressive but remain vulnerable to covariate shift: small deviations from demonstrated states can compound into task failure.